Codexis Inc., a developer of biocatalysts for the pharmaceutical and fine chemical industries, has signed a CodeEvolver platform technology license agreement with Merck, known as MSD outside the U.S. and Canada, through a subsidiary. This transaction marks the second CodeEvolver licensing agreement between Codexis and a major pharmaceutical company. Under the terms of the agreement, Codexis has granted Merck a non-exclusive license to use Codexis’ proprietary CodeEvolver protein engineering p...